When multiple myeloma relapses

RESPOND with the power* of Kyprolis® in the KRd or Kd regimen


Infusion on 2 consecutive days per week for 3 out of 4 weeks (4 week cycle):1

KRd: 10-minute infusions

Kd: 30-minute infusions

Read about KRd dosing cycles1

Read about Kd dosing cycles1

Summary of Product Characteristics


*Significant improvement in median progression-free survival with both KRd and Kd regimens.2,3

Please read the SmPC for full comprehensive safety information


  1. Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.
  2. Stewart AK et al. N Engl J Med 2015;372:142–152.
  3. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38

Terms of Use

The information contained in this site is for European healthcare professionals only.